Condition: Alzheimer's Disease · Sponsor: Hoffmann-La Roche
This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.
This description comes directly from the study's public registry record.
Reference Study ID Number: WN46072 https://forpatients.roche.com · 1-888-662-6728 · global-roche-genentech-trials@gene.com
Always discuss trial participation with your own doctor first.
| Locations not yet listed on the registry record. |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07717411